Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk stratification of patients with IgA nephropathy.

      American Journal of Kidney Diseases

      Survival Analysis, Severity of Illness Index, Risk Assessment, mortality, methods, Renal Dialysis, physiopathology, epidemiology, Proteinuria, Male, therapy, etiology, Kidney Failure, Chronic, Hypertension, Humans, Glomerulonephritis, IGA, physiology, Glomerular Filtration Rate, Follow-Up Studies, Female, Disease Progression, Cause of Death

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this review, we summarize recent advances in the risk stratification of patients with immunoglobulin A (IgA) nephropathy. Several clinical variables have consistent and independent associations with worse kidney prognosis, including blood pressure, proteinuria, and baseline kidney function. Although one-time cross-sectional assessments of blood pressure and proteinuria are important, a more thorough understanding of risk can be achieved when these variables are considered over a follow-up period. IgA nephropathy is unique compared with other glomerular diseases in that a much lower threshold of proteinuria (protein excretion, 1 g/d) is associated with glomerular filtration rate (GFR) loss. Controlling proteinuria and blood pressure over time is important to reduce the risk of future loss of kidney function. The recently described Oxford classification has helped standardize the pathologic characterization of IgA nephropathy using a scoring system that is readily reproducible and associated with increased risk of GFR loss independent of clinical variables. We suggest an approach to risk stratification in IgA nephropathy when considering potential treatment with immunosuppression. Despite our current understanding of risk stratification in IgA nephropathy, the ability to accurately predict individual patient-level risk currently is limited, and further research into additional biomarkers or risk prediction tools is needed to improve the care of patients with IgA nephropathy. Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

          Related collections

          Author and article information

          Journal
          10.1053/j.ajkd.2012.02.326
          22497792

          Comments

          Comment on this article